"10.1371_journal.pone.0075189","plos one","2013-09-11T00:00:00Z","Noemí Virgili; Pilar Mancera; Blanca Wappenhans; Georgina Sorrosal; Knut Biber; Marco Pugliese; Juan F Espinosa-Parrilla","Neurotec Pharma S.L., Bioincubadora PCB-Santander, Parc Científic de Barcelona, Barcelona, Spain; Advancell, S.A, Barcelona, Spain; Department of Psychiatry and Psychotherapy, University of Freiburg, Freiburg, Germany; Departament de Ciències Fisiològiques I, Institut dInvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain","Conceived and designed the experiments: NV KB MP JFEP. Performed the experiments: NV PM BW. Analyzed the data: NV GS JFEP. Contributed reagents/materials/analysis tools: NV PM BW. Wrote the paper: NV MP JFEP.","NV, PM, MP, JFEP have applied for a PCT application Diazoxide for use in the treatment of a central nervous system (CNS) autoimmune demyelinating disease (application number PCT/EP2011/050049). MP is CEO in Neurotec Pharma and also holds shares in the company. NV, PM, JFEP are employed in Neurotec Pharma and GS is employed in Advancell. This does not alter our adherence to all the PLOSE ONE policies on sharing data and materials. KB declares no competing interests.","2013","09","Noemí Virgili","NV",7,FALSE,4,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
